After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Dec. 10, 2010.
For these stocks trading for less than $5, a bankruptcy filing within two years is a probability.
EpiCept said it will offer 6.1 million shares of common stock at $1.10 per share.
Adam details his whereabouts on Sept. 9 and tackles readers' questions about Cyclacel, Epicept and a few more familiar names.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.